Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 4 | 4 |
| 306.43% | 233.25% | 529.28% | 889.44% | ||
| (226.01%) | (235.03%) | (114.58%) | (110.34%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(298.03%) | (309.01%) | (97.89%) | (113.57%) | |
Average Days of Receivables |
45.39 | 53.01 | 42.41 | 52.30 | |
Free Cash Flow per Share |
(0.51) | (0.50) | (0.39) | (0.40) | |
Free Cash Flow |
(22.08) | (18.85) | (20.26) | (23.24) | |
Capital Expenditures |
(0.85) | (0.84) | (0.26) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(76.87%) | (96.06%) | (19.78%) | (27.06%) | |
Accounts Receivable Turnover |
8.11 | 7.75 | 8.41 | 7.49 | |
Accounts Payable Turnover |
2.45 | 2.64 | 1.90 | 2.26 | |
Inventory Turnover |
1.76 | 1.96 | 1.69 | 1.60 | |
Average Days of Payables |
215.17 | 157.32 | 230.55 | 214.41 | |
Days of Inventory on Hand |
186.28 | 161.25 | 205.82 | 239.59 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
36.87% | 33.14% | 33.78% | 32.45% | |
Selling, General and Administrative Expense of Revenue |
124.90% | 111.11% | 113.74% | 121.02% | |
Share Based Compensation of Revenue |
21.47% | 20.22% | 22.24% | 23.75% | |
Interest Coverage |
(6.06) | (4.86) | (4.86) | (5.23) | |
Operating CF/Net income |
0.29 | 0.26 | 0.35 | 0.40 | |
Depreciation/Fixed assets |
0.90 | 0.93 | 0.87 | 0.95 | |
Capex/Depreciation |
(0.52) | (0.50) | (0.16) | (0.25) | |
Revenue per Share |
0.93 | 1.19 | 0.87 | 0.77 | |
Operating CF per Share |
(0.49) | (0.48) | (0.39) | (0.39) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 |
Columns are period end dates